Noncompetitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1
    2.
    发明申请
    Noncompetitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1 审中-公开
    绑定白细胞介素1受体1型的非竞争性结构域抗体格式

    公开(公告)号:US20090155283A1

    公开(公告)日:2009-06-18

    申请号:US12085920

    申请日:2006-11-30

    摘要: The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1α and/or IL-1β) to the receptor but do not inhibit binding of IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resistand dAb monomers, and to ligands comprising protease resistant dAb monomers. The invention also relates to nucleic acids including vectors that encode the dAb monomers and ligand, to host cells that comprise the nucleic acids and to method for producing a dAb monomer or ligand. The invention also relates to pharmaceutical compositions that comprise the dAb monomers or ligands, and to therapeutic methods that comprise administering a dAb monomer of ligand.

    摘要翻译: 本发明涉及结合IL-1R1并抑制IL-1(例如IL-1α和/或IL-1β)与受体结合但不抑制IL-1ra与IL-1R1结合的dAb单体, 包含这种dAb单体的配体。 本发明涉及蛋白酶抗性和dAb单体以及包含抗蛋白酶dAb单体的配体。 本发明还涉及包含编码dAb单体和配体的载体,包含核酸的宿主细胞的核酸以及用于产生dAb单体或配体的方法。 本发明还涉及包含dAb单体或配体的药物组合物以及包含施用配体的dAb单体的治疗方法。

    Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue
    4.
    发明授权
    Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue 有权
    用于结合肺组织中靶标的试剂靶向肺部疾病的方法

    公开(公告)号:US08497244B2

    公开(公告)日:2013-07-30

    申请号:US13356228

    申请日:2012-01-23

    IPC分类号: A61K38/00

    摘要: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g., inhaler, intranasal delivery device) for the treatment or prevention of lung inflammation or a respiratory disease, and a delivery device for the treatment or prevention of lung inflammation or a respiratory disease that contains an agent as described herein.

    摘要翻译: 公开了结合肺组织中的靶标以制备用于局部递送至肺组织的长效或长治疗窗口制剂的试剂(例如,抗体片段,拮抗剂,配体,dAb单体)的用途,以及用于施用 将肺组织中的靶标结合到受试者以在肺组织中产生长治疗窗的药剂。 该制剂用于,并且该方法包括局部给予肺组织。 还公开了使用TNFR1的拮抗剂来制造用于治疗,预防或抑制肺部炎症或呼吸系统疾病的制剂或药物,以及治疗这些疾病的方法。 还公开了使用试剂a来制造用于治疗或预防肺部炎症或呼吸系统疾病的输送装置(例如,吸入器,鼻内递送装置),以及用于治疗或预防肺部炎症或 包含本文所述的药剂的呼吸系统疾病。